Perrigo Company plc (PRGO) Operating Margin
- Operating margin · 12 months: Value -37.72%; Formula and calculation Operating income / revenue. Period ending 2026-06-27..
Operating margin
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -37.72% | Operating income / revenue. Period ending 2026-06-27. $-1.56B ÷ $4.14B × 100 ≈ -37.72% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -1.56B USD | Operating Income (Loss) |
| Revenue | 4.14B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 2.77B USD | Cost of Goods and Services Sold |
| Research and development | 95.10M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-27 | $-1.56B | $4.14B | $2.77B | $95.10M | (m) | -37.72% |
| 2026-03-28 | $-1.54B | $4.18B | $2.75B | $93.30M | (m) | -36.89% |
| 2025-12-31 | $-1.12B | $4.25B | $2.76B | $95.40M | (m) | -26.39% |
| 2025-09-27 | $279.10M | $4.28B | $2.76B | $101.40M | (m) | 6.52% |
| 2025-06-28 | $286.90M | $4.33B | $2.78B | $102.50M | (m) | 6.63% |
| 2025-03-29 | $215.00M | $4.34B | $2.76B | $109.90M | (m) | 4.96% |
| 2024-12-31 | $112.90M | $4.37B | $2.83B | $112.20M | (m) | 2.58% |
| 2024-09-28 | $-16.90M | $4.39B | $2.81B | $114.00M | (m) | -0.38% |
| 2024-06-29 | $-35.20M | $4.43B | $2.84B | $117.60M | (m) | -0.79% |
| 2024-03-30 | $48.20M | $4.56B | $2.93B | $120.40M | (m) | 1.06% |
| 2023-12-31 | $151.90M | $4.66B | $2.98B | $122.50M | (m) | 3.26% |
| 2023-09-30 | $198.50M | $4.65B | $3.02B | $125.50M | (m) | 4.27% |
| 2023-07-01 | $169.50M | $4.63B | $3.04B | $125.60M | (m) | 3.66% |
| 2023-04-01 | $105.70M | $4.56B | $3.03B | $124.90M | (m) | 2.32% |
| 2022-12-31 | $78.90M | $4.45B | $3.00B | $123.10M | (m) | 1.77% |
| 2022-10-01 | $94.60M | $4.40B | $2.97B | $120.80M | (m) | 2.15% |
| 2022-07-02 | $499.80M | $4.34B | $2.94B | $118.70M | (m) | 11.51% |
| 2022-04-02 | $380.70M | $4.20B | $2.82B | $120.20M | (m) | 9.06% |
| 2021-12-31 | $410.40M | $4.14B | $2.72B | $122.00M | (m) | 9.92% |
| 2021-10-02 | $251.50M | $5.06B | $3.30B | $180.70M | (m) | 4.97% |
| 2021-07-03 | $-108.30M | $5.02B | $3.23B | $183.50M | (m) | -2.16% |
| 2021-04-03 | $80.40M | (m) | $3.20B | $180.90M | (m) | (m) |
| 2020-12-31 | $115.40M | $5.06B | $3.25B | $177.70M | (m) | 2.28% |
| 2020-09-30 | (m) | $5.10B | (m) | (m) | (m) | (m) |
| 2020-09-26 | $160.70M | $5.10B | $3.27B | $191.00M | (m) | 3.15% |
| 2020-06-30 | (m) | $5.07B | (m) | (m) | (m) | (m) |
| 2020-06-27 | $310.60M | $5.07B | $3.26B | $192.40M | (m) | 6.12% |
| 2020-03-31 | (m) | $5.00B | (m) | (m) | (m) | (m) |
| 2020-03-28 | $248.20M | $5.00B | $3.20B | $189.10M | (m) | 4.96% |
| 2019-12-31 | $204.80M | $4.84B | $3.06B | $187.40M | (m) | 4.23% |
| 2019-09-28 | $319.20M | $4.71B | $2.97B | $172.60M | (m) | 6.78% |
| 2019-06-29 | $142.90M | $4.65B | $2.90B | $172.30M | (m) | 3.07% |
| 2019-03-30 | $182.50M | $4.69B | $2.90B | $220.40M | (m) | 3.89% |
| 2018-12-31 | $236.50M | $4.73B | $2.90B | $218.60M | (m) | 5.00% |
| 2018-09-29 | $287.60M | $4.82B | $2.92B | $220.90M | (m) | 5.97% |
| 2018-06-30 | $571.80M | $4.92B | $2.94B | $215.70M | (m) | 11.63% |
| 2018-03-31 | $626.00M | $4.97B | $2.96B | $166.30M | (m) | 12.60% |
| 2017-12-31 | $598.20M | $4.95B | $2.97B | $167.70M | (m) | 12.09% |
| 2017-09-30 | $-45.00M | $4.99B | $3.04B | $162.30M | (m) | -0.90% |
| 2017-07-01 | $-1.68B | $5.02B | $3.08B | $174.10M | (m) | -33.35% |
| 2017-04-01 | $-1.64B | $5.13B | $3.14B | $178.50M | (m) | -31.98% |
| 2016-12-31 | $-2.00B | $5.28B | $3.23B | $184.00M | (m) | -37.87% |
| 2016-10-01 | $-1.67B | $5.64B | (m) | $189.10M | (m) | -29.67% |
| 2016-07-02 | $29.00M | $5.63B | (m) | $180.50M | (m) | 0.51% |
| 2016-04-02 | (m) | $5.68B | (m) | (m) | (m) | (m) |
| 2015-12-31 | $520.70M | $5.35B | (m) | $186.20M | (m) | 9.73% |
| 2015-09-26 | $799.10M | $5.00B | (m) | $192.80M | (m) | 15.99% |
| 2015-06-27 | $747.70M | $4.60B | (m) | $187.80M | (m) | 16.24% |
| 2015-03-28 | $718.20M | $4.22B | $2.72B | $163.20M | (m) | 17.03% |
| 2014-12-27 | $622.30M | $4.17B | $2.74B | $172.50M | (m) | 14.92% |
| 2014-09-27 | $524.50M | $4.08B | $2.67B | $156.80M | (m) | 12.86% |
| 2014-06-28 | $567.00M | $4.06B | $2.61B | $152.50M | (m) | 13.96% |
| 2014-03-29 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-28 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-28 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-29 | $679.10M | $3.54B | $2.26B | $115.20M | (m) | 19.18% |
| 2013-03-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-29 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-29 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $569.20M | $3.17B | $2.08B | $105.80M | (m) | 17.94% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |